🇺🇸 FDA

Intelligence Platform

Patents

Browse 1,444 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9611322

Fusions of antibodies to CD38 and attenuated interferon alpha

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Apr 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9611230

1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the tre

PTC THERAPEUTICS, INC. · Granted Tue Apr 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9605077

Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic canc

PRECISION BIOLOGICS, INC. · Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9605263

Compositions for modulating C9ORF72 expression

Ionis Pharmaceuticals, Inc. · Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9605259

Compounds and methods for modulating protein expression

Ionis Pharmaceuticals, Inc. · Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9592207

Intranasal administration of ketamine to treat depression

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9593333

Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (L

Ionis Pharmaceuticals, Inc. · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9593151

Use of fusion protein

East China University of Science and Technology · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9592309

Positron emission tomography probe to monitor selected sugar metabolism in vivo

The Regents of the University of California · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9592290

Monoclonal antibody therapy for pancreas cancer

PRECISION BIOLOGICS, INC. · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9592255

Scaffold-free three dimensional nerve fibroblast constructs

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9587240

Compositions and methods for inhibiting expression of a target gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9574193

Methods and compositions for modulating apolipoprotein (a) expression

Ionis Pharmaceuticals, Inc. · Granted Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9574191

Selective inhibition of polyglutamine protein expression

The Board of Regents of the University of Texas System · Granted Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9567592

Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a

The Regents of the University of California · Granted Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9567588

Modulation of androgen receptor expression

Ionis Pharmaceuticals, Inc. · Granted Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9567587

Antisense modulation of GCCR expression

Ionis Pharmaceuticals, Inc. · Granted Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9566295

GNAQ targeted dsRNA compositions and methods for inhibiting expression

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9561229

Emulsion formulations of aprepitant

Heron Therapeutics, Inc. · Granted Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9556244

Vaccination of animals to elicit a protective immune response against tick infestations an

The United States of America, as represented by the Secretary of Agriculture · Granted Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9546368

Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT-1)

Ionis Pharmaceuticals, Inc. · Granted Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9526882

Percutaneous administration device and method for producing the same

OPTNICS PRECISION CO., LTD. · Granted Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9522137

Methods for dosing an orally active 1,2,4-Oxadiazole for nonsense mutation suppression the

PTC THERAPEUTICS, INC. · Granted Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9522910

Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a p

OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU “FUSION PHARMA” · Granted Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted